Jens Voortman

6PUBLICATIONS
37CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical virologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 22, 2024
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.

Niels E Wondergem, Iris H C Miedema, Rieneke van de Ven

|Feb 14, 2024
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.

Maud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht

|Nov 27, 2023
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol.

Anouk W M A Schaeffers, Lot A Devriese, Carla H van Gils

|Jun 14, 2022
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.

Jonathan W Goldman, Sarina A Piha-Paul, Brendan Curti

|Mar 10, 2022
More than a Bubble: Extracellular Vesicle microRNAs in Head and Neck Squamous Cell Carcinoma.

Wittaya Panvongsa, D Michiel Pegtel, Jens Voortman

|Oct 07, 2021
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells.

Maud Rijnders, Hayri E Balcioglu, Debbie G J Robbrecht

Pageof 1

Frequent Collaborators

2 joint publications

Hayri E Balcioglu

2 joint publications

Debbie G J Robbrecht

2 joint publications

Geert J L H van Leenders

2 joint publications

J Alberto Nakauma-González